HOW CAN WE HELP YOU? Call 1-800-TRY-CHOP
Seif Laboratory
Researchers in the Seif Laboratory are focused on developing and implementing patient-centered interventions to improve outcomes, quality of life, and health equity for pediatric patients with leukemia.
In collaboration with the Cancer/Infectious Diseases Epidemiology working group led by Richard Aplenc, MD, PhD, MSCE, the Seif Laboratory has used administrative datasets merged with clinical trial data from the Children's Oncology Group to study outcomes in large cohorts of children with acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML).
Research Highlights
Dr. Seif and collaborators identified substantial differences in ALL induction deaths by hospital correlating with payer mix, suggesting hospital-level resources affect a hospital’s ability to keep children safe during the first month of ALL therapy.
Dr. Seif's team showed that exposure to the cardioprotectant dexrazoxane did not increase the risk of secondary leukemias in a cohort of more than 15,000 children. The European Medicines Agency overturned its previous ban of dexrazoxane for pediatric patients in 2017, in part due to this work.
Other studies in the Seif Laboratory are directed towards identifying and addressing health disparities among children receiving cancer therapy.
Leader
Alix E. Seif, MD, MPH
Associate Director of Clinical Research, Center for Childhood Cancer Research
Dr. Seif's research is focused on developing and implementing patient-centered interventions to improve outcomes, quality of life, and health equity for pediatric patients with leukemia.